Rituximab with cyclophosphamide, doxorubicin, vincristine, and prednisolone (R-CHOP) is one of the standard regimens for indolent B-cell non-Hodgkin's lymphoma (NHL). It is unclear whether the prednisolone (PSL) dosage affects the therapeutic effect or the adverse event profile. We retrospectively...
EUROHEALTH, February 5 - the State Drug Administration (nmpa) has approved the first-line clinical trial of the company's independently developed Bruton tyrosine kinase (Btk) inhibitor, orbotinib, combined with R-CHOP, in the treatment of mantle cell lymphoma (MCL), a biomedical company, ...
参考文献 [1] Cong LI. Xpo-1 Inhibitor Selinexor In Combination With Rchop Is Aneffective Chemotherapy Regimen For Patients With Double/Triple-Hit Large B- Cell Lymphoma. 2024 CSCO [2]Como C. Stucchi S, De Cesare ...
Objective To investigate the efficacy and safety of R-CHOP regimen( rituximab,cyclophosphamide,epirubicin,vincristine,prednisolone) for elderly patients with stage Ⅲ～Ⅳ diffuse large B-cell lymphoma( DLBCL).Methods Thirty-three patients aged ≥60 y diagnosed as stage Ⅲ～Ⅳ DLBCL were recruited cons...
Keywords Very elderly;Non-Hodgkin’s lymphoma;Improved CHOP regimen 近年来,非霍奇金淋巴瘤(NHL)的发病率逐年升高,国外报道老年男性的发病率从19/10万增长到 99/l0万[1],但由于老年患者,尤其是高龄(>80岁)侵袭性淋巴瘤患者,通常被排除于临床试验之外,甚至很多患者放弃治疗,故其预后较差,国内外报道较少,最佳...
In addition, this regimen has been well tolerated, even in older patients. Based upon these data, the R-CHOP regimen has now been established as the standard for initial therapy of DLBCL in older patients with DLBCL. However, issues still remain with regard to the ideal schedule of R-CHOP...
Dr. Andre Goy discusses combining novel agents with R-CHOP for the treatment of large-cell lymphoma. Andre Goy, MD For decades, R-CHOP has been the standard of care for large-cell lymphomas. While the chemotherapy regimen remains the backbone of treatment, new agents offer combination possibi...
Leukemia and LymphomaDe Renzo A, Notaro R, Pezzullo L, D'Arco A, Pagnini D, Pettinato G, Rotoli B (1998) Etoposide and idarubicin in a modified CHOP-like regimen (VICED) for aggressive non-Hodgkin's lymphomas. Leuk Lymphoma 30:153...
22% (P 2 factors) groups, respectively.Thus, it may be concluded that continuous-infusion (EPOCH) chemotherapy did not improve treatment outcome over that of the CHOP regimen for aggressive non-Hodgkin's lymphoma patients. 展开 年份: 1999 ...
Oncology A 'first-generation' combination chemotherapy regimen used for low and intermediate-grade NHLs. SeeChemotherapy,Non-Hodgkin's lymphoma,Remission. McGraw-Hill Concise Dictionary of Modern Medicine. © 2002 by The McGraw-Hill Companies, Inc. ...